Axiom Investors’s Cellectis CLLS Stock Holding History

Axiom Investors’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-37,110	Closed	-$1.05M	–	132
2018 Q3	$1.05M	Sell	37,110 -24,860	-40%	-$714K	0.03%	130
2018 Q2	$1.75M	Buy	+61,970	New	+$1.85M	0.05%	130

Other funds holding CLLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Axiom Investors's CLLS Position: Q4 2018 in Review

Axiom Investors sold out of Cellectis (CLLS) in Q4 2018, closing a stake of 37,110 shares — an estimated $1.05M sold.

Axiom Investors first reported a position in CLLS in Q2 2018 and held it in 2 quarters. The position peaked at $1.75M in Q2 2018. 65 funds tracked by Wall St. Rank hold CLLS as of Q4 2018.

Axiom Investors reported no remaining Cellectis position as of Q4 2018 after selling out during the quarter.
Axiom Investors sold 37,110 Cellectis shares in Q4 2018, an estimated $1.05M.
Axiom Investors first reported a position in Cellectis in Q2 2018 and held it in 2 quarters.
Axiom Investors's Cellectis position peaked at $1.75M in Q2 2018.
65 funds tracked by Wall St. Rank held Cellectis as of Q4 2018.

Based on Axiom Investors's 13F filing for Q4 2018, filed 14 Feb 2019.